Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Marvin J. Miller
University of Notre Dame, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hsiri Therapeutics, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Prof. Miller holds an equity interest in Hsiri Therapeutics, LLC whose focus is in creating novel cures for serious infectious diseases, including tuberculosis and non-tuberculous mycobacterial diseases. The NIH-funded research that Prof. Miller will be conducting involves the advancement of IAPC lead compounds for evaluation in non-rodent (monkey) efficacy and toward clinical development; and concurrently evaluate the therapeutic potential of the newer companion imidazo[2,1-b]thiazole-5-carboxamide (IT) series. The results of this research are intended to be submitted to laboratories for evaluation of activity against mycobacterium tuberculosis (an area of focus for Hsiri Therapeutics). The resulting technology could eventually be patented and licensed to the pharmaceutical industry of which Hsiri Therapeutics, LLC is a member. In order to eliminate the appearance of an actual or perceived conflict of interest, the University has implemented a management plan with Prof. Miller to ensure the integrity of the research that will be undertaken.
Design, Syntheses and Studies of Novel Antituberculosis Agents
Project Narrative Tuberculosis (TB) is a serious global health risk that infects more than 2,000,000,000 people worldwide and causes a death every 20 seconds! The objective of this proposal is to develop cost effective anti-TB agents. The focus is on studies of new small molecular weight compounds that are easily synthesized, non-toxic, and yet effective at inhibiting TB growth.
Filed on September 30, 2016.
Tell us what you know about Marvin J. Miller's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Marvin J. Miller filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Marvin J. Miller | University of Notre Dame | Conflict of Interest | Hsiri Therapeutics, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.